# FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number: 3235-02							
stimated average burden							
ours per response	0.5						

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)															
1. Name and Address of Reporting Person * DAVE KAUSHIK J				2. Issuer Name and Ticker or Trading Symbol Actinium Pharmaceuticals, Inc. [ATNM]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Middle) C/O ACTINIUM PHARMACEUTICALS, INC, 275 MADISON AVENUE, 7TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 04/14/2016							X Officer (give title below) Other (specify below)  CEO and Interim CFO					
(Street) NEW YORK, NY 10016				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person						
(Cit	y)	(State)	(Zip)	Table I - Non-Deriv						ivative Securities Acquired, Disposed of, or Beneficially Owned							
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year)			if Co	3. Transaction Code Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		of (D)	(D) Owned Follow Transaction(s)					Beneficial
				(Month/Day/Year)		ar)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)			(	Direct (D) or Indirect I) Instr. 4)	Ownership (Instr. 4)
Common	Stock		04/14/2016				P		8,000	A	\$ 2.02	86,500	0		1	)	
Common Stock 04/14/2016					P		2,000 A		\$ 2.01	88,500		]	)				
			Table II -					conta form	ined in display posed of	this for s a curr , or Ben	rm are i rently v eficially	not red alid O	quired MB co	of informa to respon ntrol numi	d unless the		1474 (9-02)
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. 5. Nur Transaction Deriva Code Securi		Numberivative urities quired Dispose D)	r of 6 E (A)	ptions, convertible sec 6. Date Exercisable and Expiration Date (Month/Day/Year)		ole and	7. Title of Und Securit	le and Amount derlying ities 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownersh Form of Derivati Security Direct (I or Indirect)	Beneficial Ownershi (Instr. 4)
				Code	V	(A)		Date Exercisa	Expi ble Date	iration e	Title	or Ni	mount umber Shares		(Instr. 4)	(Instr. 4)	
Options to purchase common stock	\$ 1.99	04/15/2016		A	40	),000		(1)	04/1	15/2026	Comn	14(	00,000	\$ 1.99	400,000	D	

### **Reporting Owners**

	Daniel Orient Name / Addiese	Relationships							
	Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
2	DAVE KAUSHIK J C/O ACTINIUM PHARMACEUTICALS, INC C/T5 MADISON AVENUE, 7TH FLOOR NEW YORK, NY 10016	Х		CEO and Interim CFO					

### **Signatures**



## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.